Inclusion Criteria:

- Patients with Multiple Myeloma of IgG, IgA, IgD, IgE, IgM lambda or kappa light
chain, low secretory or non-secretory disease

- WHO performance status 0,1,2,or 3

- No prior treatment of multiple myeloma

- Clear requirement of treatment (usually Durie/Salmon stage II or III)

- Anticipated life expectancy of at least 3 months

- Adequate organ function

- Minimum recovery period of 2 weeks following any major surgical procedure before
entry into this study

- Women, who are sterilized via hysterectomy or bilateral tubal ligation or at least
one year post-menopausal

- Age of at least 19 years, there is no upper age limit patients must have been
informed and must have signed an informed consent

Exclusion Criteria:

- Extramedullary plasmocytoma or solitary plasmocytoma without evidence of
dissemination of disease

- Benign monoclonal gammopathy

- Multiple myeloma of IgM without osteolytic bone lesions

- Smouldering myeloma

- More than 3 irradiation fields

- Irreversible performance status of WHO4

- Prior treatment of myeloma with any of the following: chemotherapeutic or
immunomodulatory agents, corticosteroids, antiangiogenic agents or other
investigational drugs

- Women of childbearing potential

- Preexisting peripheral polyneuropathy

- Congestive heart failure NYHA III, IV

- Acute infection requiring systemic antibiotics at study entry until resolved

- Any uncontrolled underlying medical condition (eg diabetes, glaucoma)

- Second primary malignancy (with the exception of cervical carcinoma in situ and
non-myeloma skin malignancies) unless patient has been disease-free for at least
three years